Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Study of Abatacept in Japanese Subjects With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~* The participants who completed the 169 days, full study period of Phase II (IM101-071) and were not administered other biologics between completion of IM101-071 and registration of this long-term study.~* The participants of the Phase I study (IM101-034), who received abatacept, except participants who were withdrawn from the study due to safety problems related to abatacept.~* New subjects with MTX intolerance: rheumatoid arthritis (RA) patients to whom MTX cannot be administered for safety reasons and who present an inadequate response to disease-modifying antirheumatic drugs (DMARDs;excluding MTX) or biologics (new subjects with MTX intolerance: RA patients who present an inadequate response to DMARDs).~Exclusion Criteria~* Women of childbearing potential (WOCBP) who were unwilling or unable to use an acceptable method of contraception.~* Participants who have received non approved or investigational biologics (other than abatacept from previous or ongoing studies in Japan) at registration.~* Participants who have received treatment with any investigational drug within 56 days before registration or five half-lives (whichever is the longest).~* Participants currently receiving treatment with leflunomide, mycophenolate mofetil, calcineurine inhibitors such as cyclosporine and tacrolimus, D-Penicillamine, Cyclophosphamide, or immunoadsorption columns.~* The participants who completed Phase II (IM101-071) are not applicable in the following instances at time of registration: with active vasculitis, symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, cardiac, neurological, or cerebral disease, breast cancer, or a history of cancer within the last 5 years, evidence of active or latent bacterial , viral infections, any serious or chronic, at risk of tuberculosis (TB), with any opportunistic infections, laboratory values of hemoglobin \< 8.5 g/dL, white blood cells (WBC) \< 3,000/mm\^3, Platelets \< 100,000/mm\^3, Serum creatinine \> 2 times upper limit of normal (ULN), Serum alanine transaminase or aspartate aminotransferase \> 2 times ULN.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: Participants from Phase I study (IM101-034) (Type: EXPERIMENTAL): None
- Arm 2: Participants from Phase II study (IM101-071) (Type: EXPERIMENTAL): None
- Arm 3: New Participants with Methotrexate (MTX) Intolerance (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).